Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Anthem BiosciencesNSE:ANTHEM -0.93%34 ROE % is 24.95% as of Mar. 2026, which is 15% above its 10-year median of 21.71. GuruFocus rates NSE:ANTHEM with a GF Score™ of 34/100. The stock has 2 warning signs investors should review. Among 1,250 Biotechnology companies, Anthem Biosciences ranks better than 91.36% on this metric.
The historical rank and industry rank for Anthem Biosciences's ROE % or its related term are showing as below:
NSE:ANTHEM'
s ROE % Range Over the Past 10 Years
Min: 16.67 Med: 21.71 Max: 29.93
Current: 16.67
During the past 5 years, Anthem Biosciences's highest ROE % was 29.93%. The lowest was 16.67%. And the median was 21.71%.
NSE:ANTHEM's ROE % is ranked better than 91.36% of 1250
companies
in the Biotechnology industry
Industry Median: -38.53
vs NSE:ANTHEM: 16.67
Anthem Biosciences (NSE:ANTHEM) ROE % Explanation
ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.
The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:
Note:
The net income data used here is four times the quarterly (Mar. 2026) net income data. The Revenue data used here is four times the quarterly (Mar. 2026) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Net Income is used.
Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.
Anthem Biosciences ROE % Related Terms
Anthem Biosciences ROE % Historical Data
* Premium members only.
The historical data trend for Anthem Biosciences's ROE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Anthem Biosciences's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Anthem Biosciences ROE % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Anthem Biosciences's ROE % distribution charts can be found below:
* The bar in red indicates where Anthem Biosciences's ROE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
ROE % is displayed in the 30-year financial page.
Anthem Biosciences (NSE:ANTHEM) has a ROE % of 24.95% as of Mar. 2026. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Anthem Biosciences and its competitors. This is 15% above median its historical median of 21.71. Over the past decade, Anthem Biosciences' ROE % has ranged from 16.67 to 29.93. According to the industry distribution chart, Anthem Biosciences ranks #108 out of 1250 companies in the Biotechnology industry, placing it in the top 8.6%.
Is Anthem Biosciences' ROE % too high?
Anthem Biosciences' current ROE % of 24.95% is 15% above median its 10-year median of 21.71. Over the past 10 years, this metric has ranged from a low of 16.67 to a high of 29.93. Based on the distribution chart, Anthem Biosciences ranks #108 out of 1250 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Anthem Biosciences has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does Anthem Biosciences' ROE % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Anthem Biosciences ranks #108 out of 1250 companies for ROE %. This places Anthem Biosciences in the top 9% of its industry — outperforming the majority of peers. Historically, Anthem Biosciences' own ROE % has ranged from 16.67 to 29.93 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % for a Biotechnology company?
A good ROE % depends on the Biotechnology industry context. However, ROE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % mean?
A high ROE % can signal that a stock is expensive relative to its fundamentals. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Anthem Biosciences and its competitors. Anthem Biosciences's current ROE % is 24.95%, which is 15% above median its own 10-year median of 21.71. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Anthem Biosciences stock overvalued right now?
Anthem Biosciences (NSE:ANTHEM) has a current ROE % of 24.95%. The current ROE % is 24.95%, which is 15% above median its 10-year median of 21.71. Anthem Biosciences' overall GF Score™ is 34/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % calculated?
ROE % is calculated from a company's financial statements. For Anthem Biosciences (NSE:ANTHEM), the current ROE % is 24.95% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Anthem Biosciences Ltd is an innovation-driven and technology-focused Contract Research, Development and Manufacturing Organization (CRDMO) with fully integrated operations spanning across drug discovery, development and manufacturing. It is one of the few companies in India with integrated New Chemical Entity (NCE) and New Biological Entity (NBE) capabilities across drug discovery, development, and commercial manufacturing. As a one-stop service provider, It serves a range of customers, encompassing innovator-focused emerging biotech and large pharmaceutical companies globally.
34GF Score
Get the complete analysis for NSE:ANTHEM
ROE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:ANTHEM has been successfully added to your 
